| scholarly article | Q13442814 |
| P50 | author | Alex A Adjei | Q107055463 |
| Grace K Dy | Q107067420 | ||
| Amy Whitworth | Q117264221 | ||
| Dawn DePaolo | Q117264236 | ||
| Timothy Sim | Q41072308 | ||
| P2093 | author name string | Wei Tan | |
| Austin Miller | |||
| Chi-Chen Hong | |||
| Ann Marie DiRaddo | |||
| Askia Dozier | |||
| Francine Siedlecki | |||
| Sandra M Jacob | |||
| Sidra Anwar | |||
| Sonal Admane | |||
| P2860 | cites work | A new method of classifying prognostic comorbidity in longitudinal studies: development and validation | Q29547376 |
| The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology | Q29615701 | ||
| Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience | Q33399986 | ||
| Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: issues, evidence and recommendations. | Q34166038 | ||
| Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy | Q34222508 | ||
| The Functional Assessment of Cancer Therapy scale: development and validation of the general measure | Q34361336 | ||
| Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome | Q34428449 | ||
| Quality-of-life (QoL) as a predictive biomarker in patients with advanced pancreatic cancer (APC) receiving chemotherapy: results from a prospective multicenter phase 2 trial | Q34484260 | ||
| Factors influencing quality of life in cancer patients: anemia and fatigue. | Q34749557 | ||
| National Consensus Project for Quality Palliative Care: Clinical Practice Guidelines for quality palliative care, executive summary | Q35978542 | ||
| Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. | Q50751408 | ||
| Quality of life scores: an independent prognostic variable in a general population of cancer patients receiving chemotherapy. The National Cancer Institute of Canada Clinical Trials Group. | Q53602291 | ||
| Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. | Q53658356 | ||
| Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective | Q71376212 | ||
| Depression in hospitalized cancer patients | Q71405769 | ||
| The Community Clinical Oncology Program: Its Effect on Clinical Practice | Q71794817 | ||
| Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 | Q73181866 | ||
| Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials | Q73668726 | ||
| [Does Charlson-comorbidity index correlate with short-term outcome in patients with gastric cancer?] | Q79360070 | ||
| Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index | Q80553127 | ||
| Social networks, social support, and survival after breast cancer diagnosis | Q82676936 | ||
| Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials | Q36326389 | ||
| Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience | Q36510136 | ||
| Nutritional intervention and quality of life in adult oncology patients | Q36763247 | ||
| Evaluation of two competing methods for calculating Charlson's comorbidity index when analyzing short-term mortality using administrative data | Q36881878 | ||
| Patient-physician interaction and quality of life in recently diagnosed breast cancer patients | Q36999927 | ||
| Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. | Q37016543 | ||
| The physician-patient relationship and quality of life: lessons from chronic lymphocytic leukemia | Q37098971 | ||
| Social support and cancer progression: a systematic review | Q37616741 | ||
| Responses and toxic deaths in phase I clinical trials | Q37863716 | ||
| The MOS social support survey | Q39513264 | ||
| Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer | Q40606324 | ||
| Defining the risk of toxicity in phase I oncology trials of novel molecularly targeted agents: a single centre experience | Q43536539 | ||
| Risks and benefits of phase 1 oncology trials, 1991 through 2002. | Q44741767 | ||
| Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trials | Q44989593 | ||
| Prospective validation of a prognostic score to improve patient selection for oncology phase I trials | Q46068560 | ||
| Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center | Q46195964 | ||
| The study of accrual to clinical trials: can we learn from studying who enters our studies? | Q46328948 | ||
| Nomograms to predict serious adverse events in phase II clinical trials of molecularly targeted agents | Q46716128 | ||
| Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology | Q46966919 | ||
| The role of informal and formal social support networks for patients with cancer. | Q46988820 | ||
| Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab i | Q48052421 | ||
| Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life | Q48656323 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P921 | main subject | phase I clinical trial | Q5452194 |
| P577 | publication date | 2017-06-26 | |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Quality-of-Life (QOL) during Screening for Phase 1 Trial Studies in Patients with Advanced Solid Tumors and Its Impact on Risk for Serious Adverse Events | |
| P478 | volume | 9 |
| Q47121638 | CAR-T Cell Therapy: From the Bench to the Bedside | cites work | P2860 |
Search more.